NCT04685941 - Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions

Coronary Microvascular DiseaseMyocardial Infarction

Interventions

DRUG

Drug-mediated hyperemia

Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.

OTHER

Flow-mediated hyperemia

Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.

Trial Locations (5)

11009

Hospital Universitario Puerta del Mar, Cadiz

28006

Hospital La Princesa, Madrid

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

08003

Hospital del Mar, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors

collaborator

Barcicore-Lab

UNKNOWN

lead

Fundación EPIC

OTHER